Aclarubicin (BioDeep_00000012349)

   

Chemicals and Drugs Antibiotics natural product


代谢物信息卡片


Antibiotic MA 144A1

化学式: C42H53NO15 (811.3415)
中文名称: 阿克拉霉素
谱图信息: 最多检出来源 Macaca mulatta(otcml) 72.22%

分子结构信息

SMILES: CCC1(CC(C2=C(C3=C(C=C2C1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)OC5CC(C(C(O5)C)OC6CC(C(C(O6)C)OC7CCC(=O)C(O7)C)O)N(C)C)O
InChI: InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3

描述信息

L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01D - Cytotoxic antibiotics and related substances > L01DB - Anthracyclines and related substances
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
D004791 - Enzyme Inhibitors

同义名列表

3 个代谢物同义名

Aclarubicin; Antibiotic MA 144A1; Aclacinomycin A



数据库引用编号

18 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

37 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Yihan Zhao, Shiqing Jiang, Yujun Tang, Lin Zhao. Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review. International journal of hematology. 2023 Oct; 118(4):483-488. doi: 10.1007/s12185-023-03623-w. [PMID: 37269505]
  • Seketoulie Keretsu, Swapnil P Bhujbal, Seung Joo Cho. Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation. Scientific reports. 2020 10; 10(1):17716. doi: 10.1038/s41598-020-74468-0. [PMID: 33077821]
  • Ke Li, Feng Wang, Zhao-Na Yang, Bing Cui, Ping-Ping Li, Zhen-Yu Li, Zhuo-Wei Hu, Hong-Hu Zhu. PML-RARα interaction with TRIB3 impedes PPARγ/RXR function and triggers dyslipidemia in acute promyelocytic leukemia. Theranostics. 2020; 10(22):10326-10340. doi: 10.7150/thno.45924. [PMID: 32929351]
  • Tomomi Sakai, Takuya Miyazaki, Dong-Mi Shin, Yong-Soo Kim, Chen-Feng Qi, Robert Fariss, Jeeva Munasinghe, Hongsheng Wang, Alexander L Kovalchuk, Parul H Kothari, Charles S Fermaintt, John P Atkinson, Fred W Perrino, Nan Yan, Herbert C Morse. DNase-active TREX1 frame-shift mutants induce serologic autoimmunity in mice. Journal of autoimmunity. 2017 Jul; 81(?):13-23. doi: 10.1016/j.jaut.2017.03.001. [PMID: 28325644]
  • Guangming Gong, Wenya Liu, Shudong Wang. Self-assembled albumin nanoparticles as a nanocarrier for aclacinomycin A. Nanotechnology. 2016 Nov; 27(46):465602. doi: 10.1088/0957-4484/27/46/465602. [PMID: 27749275]
  • Youpeng Jia, Jun Ji, Feng Wang, Liangang Shi, Jingbo Yu, Dong Wang. Formulation, characterization, and in vitro/vivo studies of aclacinomycin A-loaded solid lipid nanoparticles. Drug delivery. 2016 May; 23(4):1317-25. doi: 10.3109/10717544.2014.974001. [PMID: 25371296]
  • Xing-bin Dai, Xue-mei Sun, Peng-jun Jiang, Hai-wen Ni, Jian-yi Chen, Wen-xi Zhang. [Modified Shengma Biejia Decoction Combined with CAG Program for Elderly Acute Myeloid Leuke- mia Patients with Yin Deficiency Toxin Stasis Syndrome]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine. 2016 Feb; 36(2):149-54. doi: ". [PMID: 27078988]
  • Qi Qu, Limin Liu, Yanming Zhang, Xiaoli Li, Depei Wu. Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia. Leukemia research. 2015 Dec; 39(12):1353-9. doi: 10.1016/j.leukres.2015.09.014. [PMID: 26432074]
  • Wang Lu-Qun, Li Hao, Li Xiang-Xin, Li Fang-Lin, Wang Ling-Ling, Chen Xue-Liang, Hou Ming. A case of simultaneous occurrence of acute myeloid leukemia and multiple myeloma. BMC cancer. 2015 Oct; 15(?):724. doi: 10.1186/s12885-015-1743-6. [PMID: 26474569]
  • Xiao-Rong Ma, Jin Wang, Wang-Gang Zhang, Yin-Xia Chen, Xing-Mei Cao, Ai-Li He, Jie Liu, Jian-Li Wang, Liu-Fang Gu, Bo Lei, Peng-Yu Zhang, Wan-Hong Zhao, Yun Yang, Fang-Xia Wang, Yan Xu. [Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome]. Zhongguo shi yan xue ye xue za zhi. 2015 Apr; 23(2):369-74. doi: 10.7534/j.issn.1009-2137.2015.02.014. [PMID: 25948187]
  • Chan Feng, Xiaoyan Li, Chunyan Dong, Xuemei Zhang, Xie Zhang, Yong Gao. RGD-modified liposomes enhance efficiency of aclacinomycin A delivery: evaluation of their effect in lung cancer. Drug design, development and therapy. 2015; 9(?):4613-20. doi: 10.2147/dddt.s85993. [PMID: 26316700]
  • Wenjuan Yu, Liping Mao, Jiejing Qian, Wenbin Qian, Haitao Meng, Wenyuan Mai, Hongyan Tong, Yin Tong, Jie Jin. Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience. Annals of hematology. 2013 Aug; 92(8):1091-100. doi: 10.1007/s00277-013-1758-5. [PMID: 23595277]
  • Yasuto Kido, Pär Matsson, Kathleen M Giacomini. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. Journal of medicinal chemistry. 2011 Jul; 54(13):4548-58. doi: 10.1021/jm2001629. [PMID: 21599003]
  • Yan Li, Yang Luan, Xinming Qi, Ming Li, Likun Gong, Xiang Xue, Xiongfei Wu, Yuanfeng Wu, Min Chen, Guozhen Xing, Jun Yao, Jin Ren. Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting ATP hydrolysis of topoisomerase II. Toxicological sciences : an official journal of the Society of Toxicology. 2010 Dec; 118(2):435-43. doi: 10.1093/toxsci/kfq282. [PMID: 20855424]
  • Jianmin Wang, Shuqing Lü, Jianmin Yang, Xianmin Song, Li Chen, Chongmei Huang, Jun Hou, Weiping Zhang. A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China. Journal of hematology & oncology. 2009 Jul; 2(?):32. doi: 10.1186/1756-8722-2-32. [PMID: 19642997]
  • Jie Gao, Yanni Xu, Yuan Yang, Yi Yang, Zhihui Zheng, Wei Jiang, Bin Hong, Xuguang Yan, Shuyi Si. Identification of upregulators of human ATP-binding cassette transporter A1 via high-throughput screening of a synthetic and natural compound library. Journal of biomolecular screening. 2008 Aug; 13(7):648-56. doi: 10.1177/1087057108320545. [PMID: 18594022]
  • Wei Lu, Jin Wan, Qing Zhang, Zhenjue She, Xinguo Jiang. Aclarubicin-loaded cationic albumin-conjugated pegylated nanoparticle for glioma chemotherapy in rats. International journal of cancer. 2007 Jan; 120(2):420-31. doi: 10.1002/ijc.22296. [PMID: 17066446]
  • Jung Su Ryu, Hong Sub Lee, Young-Soo Hong, Jung Joon Lee, Uy Dong Sohn, Tae Yong Kim. In vivo antitumor efficacy and cardiotoxicity of novel anthracycline ID6105 (11-hydroxy-aclacinomycin X, Hyrubicin). Cancer chemotherapy and pharmacology. 2006 Jun; 57(6):811-8. doi: 10.1007/s00280-005-0118-0. [PMID: 16175393]
  • Bo-Im Yoo, Kwang Bok Ahan, Min Hee Kang, Dong-Cheul Moon, Oh-Seung Kwon, Hong Sub Lee, Jung Su Ryu, Tae Yong Kim, Sukgil Song, Youn Bok Chung. HPLC analysis and pharmacokinetic characteristics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, in rats and beagle dogs. Biological & pharmaceutical bulletin. 2005 Apr; 28(4):688-93. doi: 10.1248/bpb.28.688. [PMID: 15802811]
  • Bo-Im Yoo, Kwang Bok Ahan, Min Hee Kang, Oh-Seung Kwon, Young-Soo Hong, Jung Joon Lee, Hong Sub Lee, Jung Su Ryu, Tae Yong Kim, Dong-Cheul Moon, Sukgil Song, Youn Bok Chung. Pharmacokinetics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, after i.v. bolus multiple administration in rats. Archives of pharmacal research. 2005 Apr; 28(4):476-82. doi: 10.1007/bf02977679. [PMID: 15918523]
  • Tomonori Shiokawa, Yoshiyuki Hattori, Kumi Kawano, Yukino Ohguchi, Hiroko Kawakami, Kazunori Toma, Yoshie Maitani. Effect of polyethylene glycol linker chain length of folate-linked microemulsions loading aclacinomycin A on targeting ability and antitumor effect in vitro and in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Mar; 11(5):2018-25. doi: 10.1158/1078-0432.ccr-04-1129. [PMID: 15756028]
  • M J A de Jonge, S Kaye, J Verweij, C Brock, S Reade, M Scurr, L van Doorn, C Verheij, W Loos, C Brindley, P Mistry, M Cooper, I Judson. Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours. British journal of cancer. 2004 Oct; 91(8):1459-65. doi: 10.1038/sj.bjc.6602178. [PMID: 15452551]
  • R J Veldman, S Zerp, W J van Blitterswijk, M Verheij. N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx. British journal of cancer. 2004 Feb; 90(4):917-25. doi: 10.1038/sj.bjc.6601581. [PMID: 14970874]
  • Yasuo Hirayama, Sumio Sakamaki, Norihiro Takayanagi, Yasushi Tsuji, Tamotsu Sagawa, Hiroki Chiba, Takuya Matsunaga, Yoshiro Niitsu. [Chemotherapy with ubenimex corresponding to patient age and organ disorder for 18 cases of acute myelogeneous leukemia in elderly patients--effects, complications and long-term survival]. Gan to kagaku ryoho. Cancer & chemotherapy. 2003 Aug; 30(8):1113-8. doi: NULL. [PMID: 12938265]
  • Sanae Muraoka, Toshiaki Miura. Inactivation of mitochondrial succinate dehydrogenase by adriamycin activated by horseradish peroxidase and hydrogen peroxide. Chemico-biological interactions. 2003 Mar; 145(1):67-75. doi: 10.1016/s0009-2797(02)00239-9. [PMID: 12606155]
  • Aneta Koceva-Chyła, Adam Sokal, Katarzyna Kania, Krzysztof Gwoździński, Zofia Jóźwiak. The nitroxides pirolin and pirolid protect the plasma membranes of rat cardiomyocytes against damage induced by anthracyclines. Cellular & molecular biology letters. 2003; 8(1):171-7. doi: NULL. [PMID: 12655371]
  • Pierantonio Menna, Emanuela Salvatorelli, Rossella Giampietro, Giovanni Liberi, Giovanni Teodori, Antonio M Calafiore, Giorgio Minotti. Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclines. Chemical research in toxicology. 2002 Sep; 15(9):1179-89. doi: 10.1021/tx020055+. [PMID: 12230412]
  • Junping Wang, Yoshie Maitani, Kozo Takayama. Antitumor effects and pharmacokinetics of aclacinomycin A carried by injectable emulsions composed of vitamin E, cholesterol, and PEG-lipid. Journal of pharmaceutical sciences. 2002 Apr; 91(4):1128-34. doi: 10.1002/jps.10104. [PMID: 11948551]
  • B Chénais, M Andriollo, P Guiraud, R Belhoussine, P Jeannesson. Oxidative stress involvement in chemically induced differentiation of K562 cells. Free radical biology & medicine. 2000 Jan; 28(1):18-27. doi: 10.1016/s0891-5849(99)00195-1. [PMID: 10656287]
  • M Jedrzejczak, A Koceva-Chyła, K Gwoździński, Z Jóźwiak. Changes in plasma membrane fluidity of immortal rodent cells induced by anticancer drugs doxorubicin, aclarubicin and mitoxantrone. Cell biology international. 1999; 23(7):497-506. doi: 10.1006/cbir.1999.0399. [PMID: 10728787]
  • A Hagiwara, T Takahashi, K Sawai, C Sakakura, M Shirasu, M Ohgaki, T Imanishi, J Yamasaki, Y Takemoto, N Kageyama. Selective drug delivery to peri-tumoral region and regional lymphatics by local injection of aclarubicin adsorbed on activated carbon particles in patients with breast cancer--a pilot study. Anti-cancer drugs. 1997 Aug; 8(7):666-70. doi: 10.1097/00001813-199708000-00004. [PMID: 9311442]
  • H Anderson, M Roberge. Topoisomerase II inhibitors affect entry into mitosis and chromosome condensation in BHK cells. Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research. 1996 Jan; 7(1):83-90. doi: NULL. [PMID: 8788036]
  • T Imanishi, T Sakakibara, J Yamazaki, T Ohyama, M Shirasu, H Tsujimoto, M Ohgaki, M Shimotsuma, A Hagiwara, K Sawai. [Trial of a treatment for lymph node metastases in patients with breast cancer using aclarubicin bound to activated carbon particles]. Gan to kagaku ryoho. Cancer & chemotherapy. 1995 Sep; 22(11):1635-7. doi: NULL. [PMID: 7574780]
  • K Nibu, F Yanai, J Okamura, Y Ikuno, H Tasaka, A Matsuzaki, H Inada, H Eguchi, R Sakai, H Koga. An effective salvage regimen with aclarubicin for daunorubicin-resistant acute non-lymphocytic leukemia in children. Pediatric hematology and oncology. 1995 May; 12(3):251-8. doi: 10.3109/08880019509029566. [PMID: 7640178]
  • D Kagawa, T Nakamura, T Ueda, N Domae, H Uchino. Evaluation of oral aclarubicin treatment for tumors of the gastrointestinal track. Anticancer research. 1993 Jul; 13(4):909-13. doi: NULL. [PMID: 8352559]
  • S Ikei, M Ogawa, T Beppu, C Ohara, K Sakamoto, H Sameshima, H Arakawa, Y Yamaguchi, T Yamanaka, S Kudo. Changes in IL-6, IL-8, C-reactive protein and pancreatic secretory trypsin inhibitor after transcatheter arterial chemo-embolization therapy for hepato-cellular carcinoma. Cytokine. 1992 Nov; 4(6):581-4. doi: 10.1016/1043-4666(92)90023-k. [PMID: 1337988]
  • S Wada, H Kitamura, Y Matsuura, Y Katayama, H Ohkawa, N Kugai, K Motoyoshi, Y Fuse, N Nagata. Parathyroid hormone-related protein as a cause of hypercalcemia in a B-cell type malignant lymphoma. Internal medicine (Tokyo, Japan). 1992 Aug; 31(8):968-72. doi: 10.2169/internalmedicine.31.968. [PMID: 1335805]
  • S Shinozawa, Y Gomita, Y Araki. [Effects of anthracycline drugs (aclarubicin, daunorubicin, doxorubicin, epirubicin, pirarubicin) on mouse acute toxicity and rat liver microsomal lipid peroxidation]. Gan to kagaku ryoho. Cancer & chemotherapy. 1992 Jun; 19(6):805-9. doi: ". [PMID: 1605657]
  • T Fukushima, T Ueda, T Nakamura. [Pharmacokinetics and action mechanism of anthracyclines]. Gan to kagaku ryoho. Cancer & chemotherapy. 1992 Apr; 19(4):445-50. doi: NULL. [PMID: 1558393]
  • N S Griaznova, R M Petiushenko, I V Belianskaia, L A Saburova, Iu O Sazykin, S M Navashin. [Incorporation of an antineoplastic drug aclarubicin into liposomes in relation to the conditions of its encapsulation]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]. 1992 Apr; 37(4):22-5. doi: ". [PMID: 1417310]
  • C A Bill, K C Garrett, R Harrell, P J Tofilon. Enhancement of radiation-induced cell killing and DNA double-strand breaks in a human tumor cell line using nanomolar concentrations of aclacinomycin A. Radiation research. 1992 Mar; 129(3):315-21. doi: 10.2307/3578032. [PMID: 1542719]
  • J Tarasiuk, A Garnier-Suillerot. Kinetic parameters for the uptake of anthracycline by drug-resistant and drug-sensitive K562 cells. European journal of biochemistry. 1992 Mar; 204(2):693-8. doi: 10.1111/j.1432-1033.1992.tb16683.x. [PMID: 1541282]
  • A S Tsiftsoglou, W Wong, A I Tsamadou, S H Robinson. Cooperative effects of hemin and anthracyclines in promoting terminal erythroid maturation in K562 human erythroleukemia cells. Experimental hematology. 1991 Oct; 19(9):928-33. doi: NULL. [PMID: 1893971]
  • A Hagiwara, T Takahashi, A Iwamoto, C Yoneyama, S Matsumoto, S Muranishi. Selective distribution of aclarubicin to regional lymph nodes with a new dosage form: aclarubicin adsorbed on activated carbon particles. Anti-cancer drugs. 1991 Jun; 2(3):261-6. doi: 10.1097/00001813-199106000-00006. [PMID: 1802020]
  • S Matsumoto, A Iwamoto, C Yoneyama, A Hagiwara, T Takahashi, H Yoshikawa, S Muranishi. [Adsorption and desorption of aclarubicin into and from activated carbon particles as drug carrier--an in vitro study]. Gan to kagaku ryoho. Cancer & chemotherapy. 1991 Feb; 18(2):227-31. doi: NULL. [PMID: 1992916]
  • J T Chen, Y Hirai, Y Shimizu, K Hasumi, K Masubuchi. New cisplatin schedule in combination with aclarubicin (ACR) with high response rate in recurrent gynecological adenocarcinomas. Gynecologic oncology. 1990 Jul; 38(1):1-5. doi: 10.1016/0090-8258(90)90001-2. [PMID: 2354814]
  • Y Kobayashi, Y Usuda, Y Okutu, F Okumura, H Suzuki, G Yoshida, J Hayakawa, T Shibata. [Ventricular fibrillation after administration of aclacinomycin emulsion into mesenteric lymph nodes in a patient anesthetized with enflurane, nitrous oxide and oxygen]. Masui. The Japanese journal of anesthesiology. 1990 May; 39(5):651-5. doi: NULL. [PMID: 2384961]
  • Y Sazuka, K Yoshikawa, H Tanizawa, Y Takino. Effect of aclacinomycin on lipid peroxide levels in tissues of mice. Chemical & pharmaceutical bulletin. 1989 Dec; 37(12):3412-5. doi: 10.1248/cpb.37.3412. [PMID: 2632090]
  • Y Sazuka, H Tanizawa, Y Takino. Effect of adriamycin on DNA, RNA and protein biosyntheses in mouse tissues, in connection with its cardiotoxicity. Japanese journal of cancer research : Gann. 1989 Oct; 80(10):1000-5. doi: 10.1111/j.1349-7006.1989.tb01640.x. [PMID: 2482282]
  • T Ichihara, K Sakamoto, K Mori, M Akagi. Transcatheter arterial chemoembolization therapy for hepatocellular carcinoma using polylactic acid microspheres containing aclarubicin hydrochloride. Cancer research. 1989 Aug; 49(15):4357-62. doi: NULL. [PMID: 2472878]
  • H T Hassan, J K Rees. Triple combination of retinoic acid+aclacinomycin A+ dimethylformamide induces differentiation of human acute myeloid leukaemic blasts in primary culture. Anticancer research. 1989 May; 9(3):647-51. doi: NULL. [PMID: 2764511]
  • T Sawada, T Ebihara, K Maruyama, Y Tateyama, Y Yoshimura, S Kawakami, M Fukushima. [Balloon occluded arterial infusion (BOAI) therapy in patients with progressive cervical carcinoma]. Nihon Sanka Fujinka Gakkai zasshi. 1989 Mar; 41(3):293-300. doi: NULL. [PMID: 2471758]
  • S Umeki, Y Niki, R Soejima. Anticancer chemotherapy accelerates scalp hair loss with no androgenic involvement. Chemotherapy. 1989; 35(1):54-7. doi: 10.1159/000238635. [PMID: 2721290]
  • A Schaefer, J Boldt, J Westendorf, G Steinheider, H Marquardt. Inhibition of amino acid uptake and incorporation into proteins in Friend erythroleukemia cells by the anthracycline antitumor antibiotic aclacinomycin A. Biochemical pharmacology. 1988 Apr; 37(7):1377-82. doi: 10.1016/0006-2952(88)90797-6. [PMID: 3162677]
  • L Mazzanti, V Scalori, M Mian, M G Alessandrì, L Giovannini. Aclacinomycin tissue distribution in the rat. Chemioterapia : international journal of the Mediterranean Society of Chemotherapy. 1988 Feb; 7(1):49-52. doi: NULL. [PMID: 3378277]
  • Y Maehara, H Anai, H Kusumoto, T Kusumoto, K Sugimachi. Colorectal carcinoma in vitro is more sensitive to 1-hexylcarbamoyl-5-fluorouracil compared with six other antitumor drugs: carboquone, Adriamycin, mitomycin C, aclacinomycin A, cisplatin, 5-fluorouracil. Diseases of the colon and rectum. 1988 Jan; 31(1):62-7. doi: 10.1007/bf02552573. [PMID: 3130239]
  • H Tapiero, D Boulé, G Trincal, A Fourcade, T J Lampidis. Potentiation of adriamycin accumulation and effectiveness in adriamycin-resistant cells by aclacinomycin A. Leukemia research. 1988; 12(5):411-8. doi: 10.1016/0145-2126(88)90060-4. [PMID: 3164087]
  • S V Geodakian, A A Firsov, I P Fomina. [Pharmacokinetic study of aclarubicin. The pharmacokinetics of the preparation and its biologically active metabolites in the blood of rats]. Antibiotiki i meditsinskaia biotekhnologiia = Antibiotics and medical biotechnology. 1987 Oct; 32(10):768-72. doi: NULL. [PMID: 3480699]
  • T Konno. [Targeting chemotherapy of hepatocellular carcinoma by arterial administration of anticancer agents dissolved in lipiodol]. Gan to kagaku ryoho. Cancer & chemotherapy. 1987 Feb; 14(2):373-80. doi: NULL. [PMID: 3028275]
  • I G Kerr, S Archer, C DeAngelis, S Farrell, S Hanna, J McKee. Phase I and pharmacokinetic study of high volume intraperitoneal aclacinomycin-A (Aclarubicin). Investigational new drugs. 1987; 5(2):171-6. doi: 10.1007/bf00203543. [PMID: 3477533]
  • S Wadler, J Z Fuks, P H Wiernik. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds. Journal of clinical pharmacology. 1986 Sep; 26(7):491-509. doi: 10.1002/j.1552-4604.1986.tb02942.x. [PMID: 2944917]
  • S Ando, T Nakamura, D Kagawa, T Ueda, T Nishimura, A Kubo, H Tsutani, M Sasada, H Uchino. Pharmacokinetics of aclarubicin and its metabolites in humans and their disposition in blood cells. Cancer treatment reports. 1986 Jul; 70(7):835-41. doi: NULL. [PMID: 3459574]
  • H Fujita, K Ogawa, H Tone, H Iguchi, T Shomura, S Murata. Pharmacokinetics of doxorubicin, (2'R)-4'-O-tetrahydropyranyl-adriamycin and aclarubicin. The Japanese journal of antibiotics. 1986 May; 39(5):1321-36. doi: NULL. [PMID: 3463778]
  • T Ichihara, M Akagi, K Mori, S Ikei, K Sakamoto, S Katauchi, T Beppu, M Nokano, K Tuni. [Transcatheter hepatic arterial embolization therapy using degradable polylactic acid microspheres]. Gan to kagaku ryoho. Cancer & chemotherapy. 1985 Oct; 12(10):1944-5. doi: NULL. [PMID: 2996441]
  • K Ueda, H Jinno, H Watanabe, K Ohtaguro. [Combination effects of CDDP, ACR and HCFU on progressive urothelial tumors]. Gan to kagaku ryoho. Cancer & chemotherapy. 1985 Jun; 12(6):1318-22. doi: . [PMID: 3859251]
  • T Sakuramoto, T Miura, Y Kubota. [Sensitivity tests of anti-cancer drugs with human tumor stem cell assay. 2. The results in renal cell carcinoma and urothelial carcinoma]. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology. 1985 May; 76(5):645-8. doi: 10.5980/jpnjurol1928.76.5_645. [PMID: 4057715]
  • P Dodion, M J Egorin, C E Riggs, T A Ferraro, J M Tamburini, N R Bachur. Comparative murine metabolism and disposition of class II anthracycline antibiotics. Cancer chemotherapy and pharmacology. 1985; 15(2):153-60. doi: 10.1007/bf00257527. [PMID: 3860304]
  • M Sohda, K Fujiwara, H Saikusa, T Kitagawa, N Nakamura, K Hara, H Tone. Sensitive enzyme immunoassay for the quantification of aclacinomycin A using beta-D-galactosidase as a label. Cancer chemotherapy and pharmacology. 1985; 14(1):53-8. doi: 10.1007/bf00552726. [PMID: 3917377]
  • D A Decker, A Drelichman, M I Opipari, M Al-Sarraf. Phase II evaluation of aclacinomycin-A (NSC-208734) in adenocarcinoma of the kidney. American journal of clinical oncology. 1984 Oct; 7(5):527-8. doi: 10.1097/00000421-198410000-00026. [PMID: 6594927]
  • M Fujii, K Okabe, H Toki, Y Fujita, T Ishimitsu. [Efficacy of intrapleural treatment with aclacinomycin combined with closed tube thoracostomy for malignant pleural effusion]. Gan no rinsho. Japan journal of cancer clinics. 1984 Jul; 30(8):895-8. doi: NULL. [PMID: 6471394]
  • M J Morin, A C Sartorelli. Inhibition of glycoprotein biosynthesis by the inducers of HL-60 cell differentiation, aclacinomycin A and marcellomycin. Cancer research. 1984 Jul; 44(7):2807-12. doi: ". [PMID: 6327026]
  • H Nakazawa, C E Riggs, M J Egorin, S M Redwood, N R Bachur, R Bhatnagar, Y Ito. Continuous extraction of urinary anthracycline antitumor antibiotics with the horizontal flow-through coil planet centrifuge. Journal of chromatography. 1984 May; 307(2):323-33. doi: 10.1016/s0378-4347(00)84103-1. [PMID: 6588053]
  • G Dickneite, R Kurrle, F R Seiler, G Krajczewski, H H Sedlacek. The influence of Aclacinomycin A on the immune response and on experimental immune disorders. International journal of immunopharmacology. 1984; 6(4):307-13. doi: 10.1016/0192-0561(84)90047-x. [PMID: 6332788]
  • Y Sugimoto, H Suzuki, N Tanaka. Alteration of plasma membrane of drug-resistant tumor cells: 230-kilodalton protein identified by monoclonal antibody. Biochemical and biophysical research communications. 1983 Aug; 114(3):969-75. doi: 10.1016/0006-291x(83)90655-1. [PMID: 6577861]
  • N Tanaka. [Study of new antineoplastic antibiotics based on newly discovered action mechanisms]. Gan to kagaku ryoho. Cancer & chemotherapy. 1983 Apr; 10(4 Pt 2):1094-106. doi: . [PMID: 6191673]
  • R G Smith, A A Miller, J A Benvenuto, M Valdivieso, T L Loo. Negative-ion chemical-ionization mass spectrometry of aclarubicin analogs and characterization of two metabolites in man. Cancer treatment reports. 1983 Apr; 67(4):351-4. doi: NULL. [PMID: 6573957]
  • M J Egorin, P A Andrews, H Nakazawa, N R Bachur. Purification and characterization of aclacinomycin A and its metabolites from human urine. Drug metabolism and disposition: the biological fate of chemicals. 1983 Mar; 11(2):167-71. doi: NULL. [PMID: 6133724]
  • C Karanes, J D Young, M K Samson, L B Smith, L A Franco, L H Baker. Phase I trial of aclacinomycin-A. A clinical and pharmacokinetic study. Investigational new drugs. 1983; 1(2):173-9. doi: 10.1007/bf00172077. [PMID: 6590531]
  • Y Matsuzawa, T Kiyosaki, A Yoshimoto, T Ishikura, T Takeuchi, H Umezawa. Immunological cross-reactivities of various anthracycline antibiotics against aclacinomycin A antisera. Journal of pharmacobio-dynamics. 1982 Nov; 5(11):886-92. doi: 10.1248/bpb1978.5.886. [PMID: 6962833]
  • K Ota, T Goto, M Fukushima, Y Ariyoshi. [Optimal administration schedules of antineoplastic antibiotics based on their pharmacokinetics, with special reference to bleomycins and anthracyclines]. Gan to kagaku ryoho. Cancer & chemotherapy. 1982 Aug; 9(8):1352-61. doi: NULL. [PMID: 6191712]
  • Y Matsuzawa, T Kiyosaki, T Oki, T Takeuchi, H Umezawa. Radioimmunoassay for aclacinomycin A. Gan. 1982 Apr; 73(2):229-33. doi: . [PMID: 6956531]
  • M J Egorin, D Van Echo, B M Fox, M Whitacre, N R Bachur. Plasma kinetics of aclacinomycin A and its major metabolites in man. Cancer chemotherapy and pharmacology. 1982; 8(1):41-6. doi: 10.1007/bf00292870. [PMID: 6954015]
  • Y Sugimoto, T Nishimura, H Suzuki, N Tanaka. Alteration of membrane-associated enzymes in drug-resistant sublines of mouse lymphoblastoma L5178Y cells. The Journal of antibiotics. 1981 Sep; 34(9):1200-5. doi: 10.7164/antibiotics.34.1200. [PMID: 6173369]
  • T Ogasawara, Y Masuda, S Goto, S Mori, T Oki. High performance liquid chromatographic determination of aclacinomycin a and its related compounds. II. Reverse phase HPLC determination of aclacinomycin A and its metabolites in biological fluids using fluorescence detection. The Journal of antibiotics. 1981 Jan; 34(1):52-7. doi: 10.7164/antibiotics.34.52. [PMID: 6941958]
  • M Shirai, K Ohmori, S Hirano, H Iguchi, S Hori, H Sato. [Chronic toxicity of aclacinomycin A in rats (author's transl)]. The Japanese journal of antibiotics. 1980 Mar; 33(3):294-319. doi: NULL. [PMID: 6931239]
  • S Hirano, H Tone, T Sunaga. [Cardiotoxic study of aclacinomycin A. Subacute cardiotoxicity of aclacinomycin A and its recovery in hamsters (author's transl)]. The Japanese journal of antibiotics. 1980 Mar; 33(3):268-80. doi: ". [PMID: 6931237]
  • H Iguchi, Y Matsushita, K Ohmori, S Hirano, T Kiyosaki, S Hori, H Tone, T Oki. [Studies on the absorption, excretion and distribution of aclacinomycin A: absorption, excretion and distribution of aclacinomycin A in mice, rabbits and dogs by photometric assay (author's transl)]. The Japanese journal of antibiotics. 1980 Feb; 33(2):179-91. doi: NULL. [PMID: 6929360]
  • K Ohmori, S Hirano, S Hori. [General pharmacology of aclacinomycin A (author's transl)]. The Japanese journal of antibiotics. 1980 Feb; 33(2):192-213. doi: NULL. [PMID: 6929361]
  • H Iguchi, Y Seryu, T Kiyosaki, S Hori, H Tone, T Oki. [Studies on the absorption, excretion and distribution of aclacinomycin A: absorption, excretion and distribution of 14C- or 3H-aclacinomycin A in mice, rats and rabbits (author's transl)]. The Japanese journal of antibiotics. 1980 Feb; 33(2):169-78. doi: NULL. [PMID: 6929359]